Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.
United European Gastroenterol J
; 7(6): 750-758, 2019 07.
Article
en En
| MEDLINE
| ID: mdl-31316779
ABSTRACT
Background:
Very little is known about the impact of the wash-out period on the pharmacokinetics of a second-line biologic.Objective:
The objective of this article is to explore the impact of two different wash-out periods on the pharmacokinetics of vedolizumab and infliximab.Methods:
Patients switching from infliximab to vedolizumab were retrospectively identified. The population was divided into two groups according to wash-out period <6 weeks or >6 weeks. Vedolizumab and infliximab trough levels (TLs) were determined and correlated with clinical and biological outcomes.Results:
A total of 71 inflammatory bowel disease patients were included. At week 6, in patients previously treated with infliximab, median vedolizumab TLs were 21.9 µg/ml and 24.9 µg/ml for the <6 weeks and >6 weeks wash-out period, respectively (p = 0.31), whereas median residual infliximab TLs were 0.5 µg/ml and 0 µg/ml (p = 0.034). The rate of treatment discontinuation was similar (p = 0.64), and the infectious events were six and two for the <6 weeks and >6 weeks wash-out period, respectively (p = 0.12) by week 30.Conclusions:
This study suggests clinicians may not need to be concerned about the impact of wash-out period on the pharmacokinetics of the second-line biologic when switching infliximab to vedolizumab. More data are required on the impact of wash-out period on safety.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
United European Gastroenterol J
Año:
2019
Tipo del documento:
Article
País de afiliación:
Bélgica